Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Background: In people with overweight or obesity, long-term maintenance of weight loss is challenging. Subcutaneous (s.c.) semaglutide, a glucagon-like peptide-1 analogue, has shown clinically-relevant weight loss in a phase 2 trial in people with obesity. STEP 4 investigated the impact of continued...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Endocr Soc
Auteurs principaux: Rubino, Domenica M, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L, Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A, Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A, Dicker, Dror
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2021
Sujets:
Adipose Tissue, Appetite, and Obesity
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089318/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.129
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires